Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:MNTA
- CUSIP: 60877T10
- Web: www.momentapharma.com
Capitalization:- Market Cap: $1.18 billion
- Outstanding Shares: 74,198,000
Average Prices:- 50 Day Moving Avg: $16.80
- 200 Day Moving Avg: $15.60
- 52 Week Range: $10.50 - $19.90
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -21.20
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $116.38 million
- Price / Sales: 10.68
- Book Value: $5.25 per share
- Price / Book: 3.19
Profitability:- EBIDTA: ($74,240,000.00)
- Net Margins: -24.70%
- Return on Equity: -8.20%
- Return on Assets: -6.28%
Debt:- Current Ratio: 4.10%
- Quick Ratio: 4.10%
Misc:- Average Volume: 823,346 shs.
- Beta: 1.82
- Short Ratio: 5.78
Frequently Asked Questions for Momenta Pharmaceuticals (NASDAQ:MNTA)
What is Momenta Pharmaceuticals' stock symbol?
Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."
How were Momenta Pharmaceuticals' earnings last quarter?
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.63. The company earned $26.61 million during the quarter, compared to the consensus estimate of $21.29 million. Momenta Pharmaceuticals had a negative net margin of 24.70% and a negative return on equity of 8.20%. Momenta Pharmaceuticals's revenue for the quarter was up 34.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.35) earnings per share. View Momenta Pharmaceuticals' Earnings History.
When will Momenta Pharmaceuticals make its next earnings announcement?
Where is Momenta Pharmaceuticals' stock going? Where will Momenta Pharmaceuticals' stock price be in 2017?
8 brokers have issued 12 month price objectives for Momenta Pharmaceuticals' stock. Their predictions range from $6.00 to $26.00. On average, they expect Momenta Pharmaceuticals' share price to reach $17.00 in the next year. View Analyst Ratings for Momenta Pharmaceuticals.
What are analysts saying about Momenta Pharmaceuticals stock?
Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Momenta’s Glatopa 20mg continues to perform well. Sales of Glatopa 20mg is expected to boost results. However, the issuance of a warning letter to manufacturer Pfizer for Glatopa was disappointing. The ANDA approval is now contingent on the satisfactory resolution of the compliance observations stated in the warning letter resulting in a delay in approval. The warning letter will remain a major over hang on the shares till the issue is solved. Moreover, Glatopa faces competition from Teva’s thrice-weekly Copaxone. On the flip side, a potential submission of M923 for approval in mid-2017 will boost investor confidence. Further, Momenta may collaborate with some other company for the future development and commercialization of the drug. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/4/2017)
- 2. Cowen and Company analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)
- 3. Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
- 4. Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)
Who are some of Momenta Pharmaceuticals' key competitors?
Some companies that are related to Momenta Pharmaceuticals include Blueprint Medicines Corporation (BPMC), Emergent Biosolutions (EBS), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Genomic Health (GHDX), Esperion Therapeutics (ESPR), Genus plc (GNS), Immunomedics (IMMU), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Albany Molecular Research (AMRI), Arena Pharmaceuticals (ARNA), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA), Crispr Theraptc (CRSP), Editas Medicine (EDIT) and Spectrum Pharmaceuticals (SPPI).
Who are Momenta Pharmaceuticals' key executives?
Momenta Pharmaceuticals' management team includes the folowing people:
- Craig A. Wheeler, President, Chief Executive Officer, Director
- Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, Senior Vice President - Research, Chief Scientific Officer
- Scott M. Storer, Chief Financial Officer, Senior Vice President
- Bruce A. Leicher, Senior Vice President, General Counsel, Secretary
- Bruce L. Downey, Independent Director
- Corey N. Fishman, Independent Director
- Georges Gemayel Ph.D., Independent Director
- Steven C. Gilman Ph.D., Independent Director
- Jose-Carlos Gutierrez-Ramos Ph.D., Independent Director
Who owns Momenta Pharmaceuticals stock?
Momenta Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.94%), Whittier Trust Co. (0.14%), Strs Ohio (0.07%), Russell Investments Group Ltd. (0.07%), Louisiana State Employees Retirement System (0.04%) and Wellington Shields Capital Management LLC (0.03%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea. View Institutional Ownership Trends for Momenta Pharmaceuticals.
Who sold Momenta Pharmaceuticals stock? Who is selling Momenta Pharmaceuticals stock?
Momenta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Capstone Asset Management Co.. Company insiders that have sold Momenta Pharmaceuticals stock in the last year include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach and Richard P Shea. View Insider Buying and Selling for Momenta Pharmaceuticals.
Who bought Momenta Pharmaceuticals stock? Who is buying Momenta Pharmaceuticals stock?
Momenta Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Strs Ohio, State of Alaska Department of Revenue, Whittier Trust Co., Aperio Group LLC, Municipal Employees Retirement System of Michigan and Louisiana State Employees Retirement System. View Insider Buying and Selling for Momenta Pharmaceuticals.
How do I buy Momenta Pharmaceuticals stock?
Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Momenta Pharmaceuticals' stock price today?
One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $16.75.
MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Momenta Pharmaceuticals (NASDAQ:MNTA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 4 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.25) |
| Consensus Price Target: | $17.00 (1.49% upside) |
Analysts' Ratings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/22/2017 | Barclays PLC | Downgrade | Overweight -> Equal Weight | $20.00 -> $17.00 | High |  |
| 5/3/2017 | Cowen and Company | Reiterated Rating | Hold | $15.00 | Low | |
| 5/3/2017 | Maxim Group | Set Price Target | Sell | $6.00 | Medium | |
| 5/3/2017 | Aegis | Reiterated Rating | Hold | $17.00 | Low | |
| 5/3/2017 | Stifel Nicolaus | Lower Price Target | Buy | $30.00 -> $26.00 | Medium | |
| 2/21/2017 | Leerink Swann | Downgrade | Outperform -> Market Perform | $18.00 -> $18.00 | N/A | |
| 11/3/2016 | J P Morgan Chase & Co | Reiterated Rating | Buy | $18.00 | N/A | |
| 8/5/2016 | Brean Capital | Set Price Target | Buy | $19.00 | N/A | |
| 6/6/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | $14.00 | N/A | |
| 8/24/2015 | Sanford C. Bernstein | Reiterated Rating | Buy | | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)Earnings History by Quarter for Momenta Pharmaceuticals (NASDAQ MNTA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | | | | | | | |
| 5/2/2017 | Q1 2017 | ($1.09) | ($0.46) | $21.29 million | $26.61 million | View | Listen | |
| 2/21/2017 | Q416 | ($0.24) | $0.60 | $29.56 million | $34.20 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.29) | ($0.26) | $25.68 million | $299.14 million | View | N/A | |
| 8/4/2016 | Q216 | ($0.34) | ($0.31) | $23.55 million | $26.40 million | View | N/A | |
| 5/3/2016 | Q116 | ($0.32) | ($0.35) | $28.12 million | $19.90 million | View | N/A | |
| 2/18/2016 | Q415 | ($0.04) | ($0.43) | $30.42 million | $22.40 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.19) | ($0.44) | $31.76 million | $13.80 million | View | Listen | |
| 8/4/2015 | Q215 | ($0.39) | ($0.04) | $23.59 million | $44.90 million | View | Listen | |
| 5/1/2015 | Q115 | ($0.48) | ($0.40) | $11.70 million | $8.60 million | View | N/A | |
| 2/17/2015 | Q414 | ($0.16) | ($0.31) | $23.80 million | $21.18 million | View | Listen | |
| 11/5/2014 | Q314 | ($0.43) | ($0.56) | $13.00 million | $9.34 million | View | Listen | |
| 7/31/2014 | Q214 | ($0.49) | ($0.51) | $11.22 million | $11.00 million | View | Listen | |
| 5/6/2014 | Q1 | ($0.55) | ($0.53) | $8.41 million | $10.79 million | View | Listen | |
| 2/10/2014 | Q4 | ($0.45) | ($0.59) | $8.50 million | $12.80 million | View | Listen | |
| 11/5/2013 | Q313 | ($0.48) | ($0.50) | $8.60 million | $10.80 million | View | N/A | |
| 8/1/2013 | Q2 2013 | ($0.45) | ($0.57) | $8.85 million | $4.40 million | View | N/A | |
| 4/30/2013 | Q1 2013 | ($0.44) | ($0.48) | $10.28 million | $7.60 million | View | N/A | |
| 2/15/2013 | Q4 2012 | ($0.41) | ($0.35) | $10.41 million | $12.70 million | View | N/A | |
| 11/7/2012 | Q312 | ($0.27) | ($0.51) | $16.48 million | $5.10 million | View | N/A | |
| 8/2/2012 | | ($0.17) | ($0.20) | | | View | N/A | |
| 5/3/2012 | | $0.02 | ($0.10) | | | View | N/A | |
| 2/9/2012 | | $0.13 | ($0.02) | | | View | N/A | |
| 11/7/2011 | | $1.28 | $1.18 | | | View | N/A | |
| 8/4/2011 | | $1.21 | $1.26 | | | View | N/A | |
| 5/5/2011 | | $0.95 | $1.13 | | | View | N/A | |
| 2/10/2011 | | $0.81 | $0.77 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)2017 EPS Consensus Estimate: ($0.58)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.36) | ($0.36) | ($0.36) |
| Q2 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q3 2017 | 1 | ($0.20) | ($0.20) | ($0.20) |
| Q4 2017 | 1 | $0.28 | $0.28 | $0.28 |
(Data provided by Zacks Investment Research)
Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Momenta Pharmaceuticals (NASDAQ:MNTA)Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 86.04%
Insider Trades by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/22/2017 | Bruce Leicher | SVP | Sell | 859 | $14.80 | $12,713.20 | |
| 5/19/2017 | Craig A Wheeler | President | Sell | 4,116 | $15.83 | $65,156.28 | |
| 5/19/2017 | Ganesh Venkataraman Kaundinya | VP | Sell | 821 | $15.90 | $13,053.90 | |
| 5/10/2017 | Bruce Leicher | SVP | Sell | 347 | $16.00 | $5,552.00 | |
| 5/10/2017 | Craig A. Wheeler | President | Sell | 1,852 | $15.77 | $29,206.04 | |
| 5/10/2017 | Ganesh Venkataraman Kaundinya | VP | Sell | 384 | $16.00 | $6,144.00 | |
| 12/15/2016 | Richard P Shea | CFO | Sell | 9,799 | $15.00 | $146,985.00 | |
| 12/9/2016 | Richard P Shea | CFO | Sell | 1,451 | $15.00 | $21,765.00 | |
| 11/22/2016 | Bruce Leicher | SVP | Sell | 1,030 | $13.66 | $14,069.80 | |
| 11/22/2016 | Craig A. Wheeler | President | Sell | 5,880 | $13.68 | $80,438.40 | |
| 11/22/2016 | James M Roach | VP | Sell | 1,091 | $13.67 | $14,913.97 | |
| 11/22/2016 | Richard P Shea | CFO | Sell | 971 | $13.67 | $13,273.57 | |
| 8/22/2016 | Bruce Leicher | SVP | Sell | 1,030 | $12.05 | $12,411.50 | |
| 8/22/2016 | Craig A. Wheeler | President | Sell | 5,880 | $12.02 | $70,677.60 | |
| 8/22/2016 | James M Roach | VP | Sell | 1,091 | $12.05 | $13,146.55 | |
| 8/22/2016 | Richard P Shea | CFO | Sell | 972 | $12.05 | $11,712.60 | |
| 5/20/2016 | Bruce Leicher | SVP | Sell | 1,000 | $10.40 | $10,400.00 | |
| 5/20/2016 | Craig A Wheeler | President | Sell | 5,880 | $10.18 | $59,858.40 | |
| 5/20/2016 | Ganesh Venkataraman Kaundinya | VP | Sell | 1,050 | $10.18 | $10,689.00 | |
| 5/20/2016 | Richard P Shea | CFO | Sell | 973 | $10.18 | $9,905.14 | |
| 5/19/2016 | John E Bishop | VP | Sell | 784 | $10.20 | $7,996.80 | |
| 4/19/2016 | John E Bishop | VP | Sell | 2,843 | $9.57 | $27,207.51 | |
| 2/23/2016 | John E Bishop | VP | Sell | 329 | $9.70 | $3,191.30 | |
| 2/22/2016 | Bruce Leicher | SVP | Sell | 227 | $9.65 | $2,190.55 | |
| 2/22/2016 | Craig A Wheeler | President | Sell | 1,688 | $9.95 | $16,795.60 | |
| 2/22/2016 | John E Bishop | VP | Sell | 2,848 | $9.66 | $27,511.68 | |
| 2/19/2016 | Bruce Leicher | SVP | Sell | 2,000 | $9.64 | $19,280.00 | |
| 2/19/2016 | Craig A Wheeler | President | Sell | 9,844 | $9.37 | $92,238.28 | |
| 2/19/2016 | John E. Bishop | VP | Sell | 357 | $10.28 | $3,669.96 | |
| 2/19/2016 | Richard P Shea | CFO | Sell | 1,823 | $9.64 | $17,573.72 | |
| 2/18/2016 | Bruce Leicher | SVP | Sell | 337 | $10.49 | $3,535.13 | |
| 2/18/2016 | James M Roach | VP | Sell | 272 | $10.49 | $2,853.28 | |
| 2/18/2016 | Richard P Shea | CFO | Sell | 183 | $10.49 | $1,919.67 | |
| 2/17/2016 | Craig A Wheeler | President | Sell | 1,688 | $11.30 | $19,074.40 | |
| 12/11/2015 | Michael Franken | Insider | Sell | 520 | $15.84 | $8,236.80 | |
| 11/20/2015 | Craig A Wheeler | President | Sell | 1,766 | $17.86 | $31,540.76 | |
| 11/19/2015 | Craig A Wheeler | President | Sell | 2,061 | $18.05 | $37,201.05 | |
| 11/17/2015 | Craig A Wheeler | President | Sell | 1,766 | $17.70 | $31,258.20 | |
| 11/5/2015 | Craig A. Wheeler | President | Sell | 51,667 | $18.00 | $930,006.00 | |
| 8/20/2015 | Craig A Wheeler | President | Sell | 1,766 | $22.28 | $39,346.48 | |
| 8/19/2015 | Craig A Wheeler | President | Sell | 2,061 | $22.02 | $45,383.22 | |
| 8/19/2015 | James M. Roach | VP | Sell | 7,011 | $22.09 | $154,872.99 | |
| 8/18/2015 | James M Roach | VP | Sell | 6,812 | $21.80 | $148,501.60 | |
| 8/17/2015 | Craig A Wheeler | President | Sell | 1,766 | $21.77 | $38,445.82 | |
| 7/15/2015 | Elizabeth Stoner | Director | Sell | 4,570 | $22.35 | $102,139.50 | |
| 6/19/2015 | John E Bishop | VP | Sell | 21,274 | $25.50 | $542,487.00 | |
| 6/18/2015 | Bruce Leicher | SVP | Sell | 20,000 | $23.00 | $460,000.00 | |
| 6/18/2015 | Craig A Wheeler | President | Sell | 155,000 | $24.20 | $3,751,000.00 | |
| 6/18/2015 | John E Bishop | VP | Sell | 36,313 | $23.58 | $856,260.54 | |
| 6/4/2015 | Craig A Wheeler | President | Sell | 103,333 | $22.00 | $2,273,326.00 | |
| 6/1/2015 | Bruce Leicher | SVP | Sell | 40,000 | $21.00 | $840,000.00 | |
| 6/1/2015 | James M Roach | VP | Sell | 25,000 | $21.70 | $542,500.00 | |
| 5/20/2015 | Craig A Wheeler | President | Sell | 1,766 | $19.68 | $34,754.88 | |
| 5/19/2015 | Craig A Wheeler | President | Sell | 2,061 | $19.67 | $40,539.87 | |
| 4/23/2015 | Craig A Wheeler | President | Sell | 51,667 | $20.00 | $1,033,340.00 | |
| 4/23/2015 | Ganesh Venkataraman Kaundinya | VP | Sell | 34,000 | $19.95 | $678,300.00 | |
| 4/20/2015 | Craig A Wheeler | President | Sell | 6,269 | $18.75 | $117,543.75 | |
| 4/17/2015 | Bruce Leicher | SVP | Sell | 52,910 | $19.52 | $1,032,803.20 | |
| 4/16/2015 | James M Roach | VP | Sell | 50,000 | $18.70 | $935,000.00 | |
| 3/16/2015 | Richard P Shea | CFO | Sell | 23,093 | $15.10 | $348,704.30 | |
| 3/5/2015 | Richard P Shea | CFO | Sell | 23,364 | $14.90 | $348,123.60 | |
| 2/24/2015 | Craig A Wheeler | President | Sell | 2,110 | $13.52 | $28,527.20 | |
| 2/20/2015 | Bruce Leicher | SVP | Sell | 1,891 | $12.97 | $24,526.27 | |
| 2/20/2015 | Craig A Wheeler | President | Sell | 9,563 | $13.49 | $129,004.87 | |
| 2/20/2015 | John E Bishop | VP | Sell | 1,768 | $12.97 | $22,930.96 | |
| 2/20/2015 | Richard P Shea | CFO | Sell | 1,812 | $12.97 | $23,501.64 | |
| 2/18/2015 | Craig A Wheeler | President | Sell | 1,688 | $11.91 | $20,104.08 | |
| 12/15/2014 | Bennett M Shapiro | Director | Sell | 5,800 | $12.19 | $70,702.00 | |
| 12/11/2014 | Michael Franken | Insider | Sell | 2,047 | $12.29 | $25,157.63 | |
| 12/1/2014 | Bennett M Shapiro | Director | Sell | 9,903 | $12.00 | $118,836.00 | |
| 11/28/2014 | Bennett M Shapiro | Director | Sell | 1,897 | $12.00 | $22,764.00 | |
| 11/25/2014 | Craig A Wheeler | President | Sell | 2,210 | $11.59 | $25,613.90 | |
| 11/20/2014 | Craig A Wheeler | President | Sell | 1,768 | $11.10 | $19,624.80 | |
| 11/17/2014 | Craig A Wheeler | President | Sell | 1,768 | $10.58 | $18,705.44 | |
| 10/3/2014 | Bennett M Shapiro | Director | Sell | 3,723 | $12.00 | $44,676.00 | |
| 9/12/2014 | Peter Barton Hutt | Director | Sell | 3,640 | $11.42 | $41,568.80 | |
| 8/25/2014 | Craig A Wheeler | President | Sell | 2,209 | $11.45 | $25,293.05 | |
| 8/20/2014 | Craig A Wheeler | President | Sell | 1,768 | $11.54 | $20,402.72 | |
| 8/15/2014 | Bennett M Shapiro | Director | Sell | 3,722 | $12.00 | $44,664.00 | |
| 8/15/2014 | Craig A Wheeler | President | Sell | 1,768 | $11.75 | $20,774.00 | |
| 8/13/2014 | Bennett M Shapiro | Director | Sell | 3,721 | $12.00 | $44,652.00 | |
| 5/23/2014 | Craig A Wheeler | President | Sell | 2,110 | $12.06 | $25,446.60 | |
| 5/20/2014 | Craig Wheeler | President | Sell | 1,688 | $12.08 | $20,391.04 | |
| 5/15/2014 | Craig Wheeler | President | Sell | 1,687 | $11.09 | $18,708.83 | |
| 2/25/2014 | Craig Wheeler | President | Sell | 2,109 | $17.47 | $36,844.23 | |
| 2/24/2014 | John Bishop | VP | Sell | 1,038 | $17.67 | $18,341.46 | |
| 2/19/2014 | Craig Wheeler | President | Sell | 3,797 | $17.90 | $67,966.30 | |
| 2/12/2014 | Ganesh Venkataraman Kaundinya | VP | Sell | 33,000 | $17.96 | $592,680.00 | |
| 1/9/2014 | John Bishop | VP | Sell | 27,159 | $19.50 | $529,600.50 | |
| 11/25/2013 | Bruce Leicher | SVP | Sell | 13,492 | $18.00 | $242,856.00 | |
| 11/25/2013 | Craig Wheeler | President | Sell | 2,215 | $17.77 | $39,360.55 | |
| 11/25/2013 | Ganesh Venkataraman Kaundinya | VP | Sell | 33,211 | $18.02 | $598,462.22 | |
| 11/19/2013 | Craig Wheeler | President | Sell | 2,215 | $17.17 | $38,031.55 | |
| 11/15/2013 | Craig Wheeler | President | Sell | 1,772 | $16.88 | $29,911.36 | |
| 10/11/2013 | John Bishop | VP | Sell | 5,247 | $15.46 | $81,118.62 | |
| 8/23/2013 | Craig Wheeler | President | Sell | 2,109 | $14.90 | $31,424.10 | |
| 8/20/2013 | Craig Wheeler | President | Sell | 2,109 | $14.47 | $30,517.23 | |
| 8/15/2013 | Craig Wheeler | President | Sell | 1,688 | $15.43 | $26,045.84 | |
| 7/26/2013 | Richard P Shea | CFO | Sell | 30,000 | $16.61 | $498,300.00 | |
| 6/27/2013 | Richard P Shea | CFO | Sell | 10,522 | $14.61 | $153,726.42 | |
| 6/19/2013 | Richard P Shea | CFO | Sell | 21,550 | $14.61 | $314,845.50 | |
| 5/23/2013 | Craig A Wheeler | President | Sell | 2,109 | $13.03 | $27,480.27 | |
| 5/21/2013 | Craig A Wheeler | President | Sell | 2,109 | $12.83 | $27,058.47 | |
| 5/15/2013 | Craig A Wheeler | President | Sell | 1,687 | $13.33 | $22,487.71 | |
| 3/5/2013 | Elizabeth Stoner | Director | Sell | 2,040 | $14.00 | $28,560.00 | |
| 2/15/2013 | Bruce Leicher | SVP | Sell | 1,040 | $12.26 | $12,750.40 | |
(Data available from 1/1/2013 forward)
Headline Trends for Momenta Pharmaceuticals (NASDAQ:MNTA)
Latest Headlines for Momenta Pharmaceuticals (NASDAQ:MNTA)
| Source: |
|
| Date | Headline |
|---|
 | Momenta Phama (MNTA) is 'Disappointed' by Jury Verdict in Enoxaparin Sodium Injection Patent Litigation
www.streetinsider.com - July 22 at 6:35 AM |
 | Momenta Pharmaceuticals Announces Date of Second Quarter 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - July 20 at 1:26 AM |
 | Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 11:34 AM |
| ETFs with exposure to Momenta Pharmaceuticals, Inc. : July 10, 2017
finance.yahoo.com - July 11 at 2:14 AM |
| Momenta Pharmaceuticals, Inc. (MNTA) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - July 6 at 9:04 PM |
| Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 4 at 1:41 PM |
| ETFs with exposure to Momenta Pharmaceuticals, Inc. : June 27, 2017
finance.yahoo.com - June 27 at 6:44 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - June 23 at 7:38 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 20 at 10:46 AM |
| Investors Purchase High Volume of Momenta Pharmaceuticals Put Options (MNTA)
www.americanbankingnews.com - June 16 at 8:25 AM |
| Mylan In FDA Limbo On Generic Multiple Sclerosis Drug
finance.yahoo.com - June 16 at 7:49 AM |
| Implied Volatility Surging for Momenta Pharmaceuticals (MNTA) Stock Options
finance.yahoo.com - June 13 at 6:44 PM |
| ETFs with exposure to Momenta Pharmaceuticals, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 3:58 PM |
| Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 6:47 PM |
| Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference
finance.yahoo.com - June 7 at 9:05 AM |
| Why Is Momenta Pharmaceuticals (MNTA) Down 9.7% Since the Last Earnings Report?
finance.yahoo.com - June 5 at 9:17 AM |
| Momenta Phama (MNTA) Appoints Santiago Arroyo as CMO
www.streetinsider.com - June 1 at 7:25 PM |
| Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer
finance.yahoo.com - June 1 at 9:21 AM |
| Novartis warns of U.S. price pressure on Sandoz generics
finance.yahoo.com - May 31 at 7:58 AM |
| Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 26 at 10:50 AM |
| Insider Selling: Momenta Pharmaceuticals, Inc. (MNTA) VP Sells 821 Shares of Stock
www.americanbankingnews.com - May 23 at 4:46 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) SVP Bruce Leicher Sells 859 Shares
www.americanbankingnews.com - May 23 at 4:46 PM |
| Insider Selling: Momenta Pharmaceuticals, Inc. (MNTA) President Sells 4,116 Shares of Stock
www.americanbankingnews.com - May 23 at 4:34 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) Stock Rating Lowered by Barclays PLC
www.americanbankingnews.com - May 22 at 4:29 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) President Craig A. Wheeler Sells 1,852 Shares
www.americanbankingnews.com - May 12 at 4:26 PM |
| UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
finance.yahoo.com - May 10 at 6:40 PM |
| Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
finance.yahoo.com - May 10 at 12:21 PM |
| Maxim Group Reiterates "$6.00" Price Target for Momenta Pharmaceuticals, Inc. (MNTA)
www.americanbankingnews.com - May 7 at 9:28 PM |
| Edited Transcript of MNTA earnings conference call or presentation 2-May-17 2:00pm GMT
finance.yahoo.com - May 3 at 10:39 PM |
| Momenta Pharmaceuticals' (MNTA) "Hold" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - May 3 at 7:14 PM |
| Momenta Pharmaceuticals, Inc. Looks for Some Momentum
finance.yahoo.com - May 3 at 5:39 PM |
| Somewhat Favorable Media Coverage Likely to Impact Momenta Pharmaceuticals (MNTA) Share Price
www.americanbankingnews.com - May 3 at 3:30 PM |
| Investor Network: Momenta Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 7:09 PM |
| Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 7:09 PM |
| Momenta reports 1Q loss
finance.yahoo.com - May 2 at 7:09 PM |
| Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : May 2, 2017
finance.yahoo.com - May 2 at 7:09 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) Issues Earnings Results
www.americanbankingnews.com - May 2 at 4:34 PM |
| Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : May 1, 2017
finance.yahoo.com - May 1 at 12:35 PM |
| Momenta Pharmaceuticals (MNTA) Earning Somewhat Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 4:11 PM |
| Momenta Pharmaceuticals, Inc. (MNTA) Short Interest Update
www.americanbankingnews.com - April 29 at 10:10 AM |
| Momenta Pharmaceuticals (MNTA) Earns Coverage Optimism Rating of 0.16
www.americanbankingnews.com - April 28 at 1:04 AM |
| Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 26 at 6:43 PM |
| Somewhat Critical News Coverage Very Likely to Impact Momenta Pharmaceuticals (MNTA) Share Price
www.americanbankingnews.com - April 24 at 2:38 PM |
| Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - April 18 at 10:22 AM |
| Why Is Momenta (MNTA) Down 9.6% Since the Last Earnings Report?
finance.yahoo.com - March 29 at 9:45 AM |
| Short Interest in Momenta Pharmaceuticals, Inc. (MNTA) Decreases By 36.4%
www.americanbankingnews.com - March 27 at 7:17 AM |
| Teva Pharma Denies Rumors of Global Workforce Reduction
finance.yahoo.com - March 24 at 6:36 PM |
| MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina
biz.yahoo.com - March 17 at 6:45 PM |
 | Momenta Pharmaceuticals (MNTA) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 8 at 7:20 PM |
| MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 8 at 10:03 AM |
Momenta Pharmaceuticals (MNTA) Chart for Wednesday, July, 26, 2017
